SKIN & AESTHETICS / COMPARE
GHK-Cu and GLOW, Side by Side
Where the two entries on this desk overlap, where they diverge, and — most importantly — how far the evidence behind each one actually reaches.
The short version
This page lines up GHK-Cu and the GLOW research blend on the dimensions that matter most when reading about research peptides: what kind of molecule each is, where it has been studied, how strong that evidence is, how it was given in studies, its regulatory standing, and its single biggest caution.
The headline comparison is straightforward. GHK-Cu is the more established compound — a legal cosmetic ingredient with decades of topical use and small but real controlled human data on skin firmness and hair growth. GLOW is a non-standardized combination of three peptides (including GHK-Cu) whose rationale rests on single-constituent research extrapolated to a blend that has never itself been studied in a controlled human trial. Both are presented here as research subjects, not products to seek out or purchase.
The comparison matrix
| Dimension | GHK-Cu | GLOW (research blend) |
|---|---|---|
| Composition | Single molecule: copper tripeptide-1, glycyl-L-histidyl-L-lysine Cu(II) (3 aa + Cu) | Three-peptide co-formulation: GHK-Cu + BPC-157 (15 aa) + TB-500 (7 aa) |
| Drug / ingredient class | Copper-binding peptide; legal cosmetic ingredient (topical); research peptide (systemic) | Multi-peptide research blend; no unified drug class; constituents are unapproved research chemicals (except cosmetic-route GHK-Cu) |
| Most studied for | Skin regeneration, collagen/elastin synthesis, hair follicle activity, matrix remodeling | Skin renewal (GHK-Cu arm), angiogenesis and vascular repair (BPC-157 arm), cell migration and anti-scarring (TB-500 arm) — claimed together, never tested together |
| Strongest human evidence | Topical: placebo-controlled improvement in collagen production, skin laxity, fine lines; one 45-patient hair-loss combination RCT [4][3] | No controlled human trial of the blend itself; only constituent-level human data [8][9] |
| Evidence model | Human topical trials (small) + human fibroblast cultures + animal | Animal models (overwhelmingly) + 3 small human BPC-157 pilots + GHK-Cu topical data [8][9] |
| Regulatory status | Topical: legal cosmetic ingredient (US, EU, UK). Systemic/injectable: unapproved, research-only [1] | Not approved by any regulator. BPC-157 flagged by FDA 2023 as not eligible for compounding pending evaluation; TB-500 similarly unapproved [8] |
| WADA status | Not currently on WADA Prohibited List; catch-all S0 may apply — verify current list | PROHIBITED for athletes: TB-500 (WADA S2 peptide/growth factor); BPC-157 (WADA S0 non-approved) [8] |
| Key caution | Poor skin permeability without delivery aids; thin systemic human evidence; single-investigator research concentration [1] | Blend is untested in humans; inherits investigational framing of BPC-157 (most data-poor arm); TB-500 and BPC-157 carry WADA prohibition [8][9] |
Evidence depth
The two diverge most sharply on human evidence. GHK-Cu has decades of topical cosmetic use behind it, small placebo-controlled trials showing improvements in collagen production (70% of GHK-Cu-treated subjects versus 50% for vitamin C and 40% for retinoic acid in comparative studies [1][4]), and a controlled 45-patient hair-growth RCT using a GHK-containing combination product [3]. That is modest but real human footing.
GLOW, as a blend, has none. Its evidence lives at two levels: the single-constituent literature for each of GHK-Cu, BPC-157, and TB-500 — individually studied but separately, not together — and the mechanistic combination rationale. A 2026 Sports Medicine review naming all three constituents is explicit that favorable animal results have not been matched by rigorous human data and that a gray market operates largely outside regulatory oversight [8]. The GLOW blend inherits whatever the BPC-157 literature says: a 2025 narrative review found only three small human pilot studies, no adverse effects reported but no controlled efficacy trials, and labeled it investigational [9].
Regulatory and anti-doping
The regulatory picture is where the two differ most practically. Topical GHK-Cu (copper tripeptide-1) is a legal, widely available cosmetic ingredient in the US, EU, and UK. Systemic or injectable GHK-Cu is unapproved and research-only — the FDA has no approved drug product for any route [1].
For GLOW, the strictest component sets the regulatory floor. BPC-157 and TB-500 are both unapproved research chemicals — not approved drugs, not supplements. The FDA in 2023 flagged BPC-157 as not eligible for pharmacy compounding pending further evaluation. Both BPC-157 and TB-500 (thymosin beta-4 fragment) are explicitly prohibited by WADA in sport: TB-500 under class S2 (peptide hormones, growth factors and mimetics) and BPC-157 under S0 (non-approved pharmacological substances), banned at all times [8]. Any athlete subject to anti-doping testing should treat GLOW as categorically off-limits.
Which story this desk is really about
For skin firmness and elasticity research, GHK-Cu carries the published evidence — the fibroblast collagen-synthesis data, the gene-expression profiling, the topical human improvements in fine lines and skin quality. Its limits are real: it does not cross intact skin easily, its human trials are small and topical, and the broader systemic claims outpace the evidence [1]. That is the honest frontier of what copper-peptide research currently offers.
GLOW adds two more repair mechanisms to that foundation and makes a combination argument for broader tissue renewal — but remains a clinical hypothesis rather than a tested answer. Reading them together is more useful than reading either alone: GHK-Cu shows what the matrix-building signal does in humans; GLOW shows how researchers and clinics are thinking about combining that signal with vascular and cell-migration support. The controlled evidence for the combination still needs to be written.